Creative BioMart to Present at
                        BIO-Europe Spring Creative BioMart to Present at AACR Annual Meeting|Apr. 5-10, 2024|Booth #2953

Active Recombinant Mouse Lgals9

Cat.No. : Lgals9-695M
Product Overview : Recombinant Mouse Lgals9 (Accession # NP_001152773) Ala2-Thr322 was produced in E. coli-derived.
  • Specification
  • Gene Information
  • Related Products
Source : E. coli
Species : Mouse
Predicted N Terminal : Ala2
Form : Lyophilized from a 0.2 µm filtered solution in MOPS, NaCl, EDTA, DTT and Trehalose.
Bio-activity : Measured by the ability of the immobilized protein to support the adhesion of D10.G4.1 mouse helper T cells.The ED50 for this effect is typically 0.6-3 µg/mL.
Molecular Mass : Recombinant Mouse Lgals9 has a calculated MW of 36.4 kDa. In SDS-PAGE migrates as 36 kDa, reducing conditions.
Purity : >95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Storage : Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).
Gene Name : Lgals9 lectin, galactose binding, soluble 9 [ Mus musculus ]
Official Symbol : Lgals9
Synonyms : LGALS9; lectin, galactose binding, soluble 9; galectin-9; lectin, galactose binding, soluble 5; gal-9; Lgals5; LGALS35; AA407335; AI194909; AI265545;
Gene ID : 16859
mRNA Refseq : NM_001159301
Protein Refseq : NP_001152773
MIM :

For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.

Inquiry

  • Q&As
  • Reviews

Q&As (5)

Ask a question
Are there any ongoing clinical trials involving LGALS9 protein? 04/12/2023

Yes, there are clinical trials investigating the use of LGALS9-based therapies in cancer treatment, with a focus on immunotherapy approaches.

Is LGALS9 protein being explored for the treatment of infectious diseases? 07/05/2022

There is emerging research on the potential use of LGALS9 in modulating immune responses to infectious diseases, particularly in the context of viral infections.

What are the potential challenges associated with the clinical application of LGALS9 protein? 03/28/2021

Challenges include optimizing the delivery and dosing of LGALS9-based therapies and addressing potential adverse effects on immune homeostasis.

How is LGALS9 protein being studied in the context of transplant immunology? 01/08/2020

LGALS9 is being investigated for its potential to induce immune tolerance and mitigate transplant rejection in preclinical studies.

How does LGALS9 protein contribute to cancer immunotherapy? 12/31/2019

LGALS9 has been found to promote the activation and proliferation of cytotoxic T lymphocytes, which are key players in the immune response against cancer cells.

Customer Reviews (3)

Write a review
Reviews
08/04/2019

    It has demonstrated outstanding performance in ELISA, providing reliable and precise results.

    05/05/2019

      It has been invaluable in protein electron microscopy structure analysis, facilitating detailed investigations and yielding valuable insights.

      03/09/2016

        I highly recommend the LGALS9 protein for various experimental applications.

        Ask a Question for All Lgals9 Products

        Required fields are marked with *

        My Review for All Lgals9 Products

        Required fields are marked with *

        0

        Inquiry Basket

        cartIcon
        logo

        FOLLOW US

        Terms and Conditions        Privacy Policy

        Copyright © 2024 Creative BioMart. All Rights Reserved.

        Contact Us

        • /

        Stay Updated on the Latest Bioscience Trends